DMII
Drugs Made In America Acquisition II Corp.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
Drugs Made In America Acquisition II Corp.
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
No N-PORT holders.
No thesis.
Largest filed tie
0
filed ties
—
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Karpus ManagementKarpus | $28.0M | 6.13% | +7.32% | |
| 2 | MMCAP International Inc. SPCMMCAP International Inc. SPC | $27.2M | 5.94% | 0.00% | |
| 3 | Magnetar FinancialMagnetar Financial | $27.2M | 5.94% | 0.00% | |
| 4 | Glazer CapitalGlazer Capital | $23.6M | 5.15% | −0.28% | |
| 5 | Highbridge Capital ManagementHighbridge | $22.6M | 4.93% | +896.08% | |
| 6 | Millennium ManagementMillennium | $20.1M | 4.38% | +0.87% | |
| 7 | Hudson Bay Capital ManagementHudson Bay | $19.8M | 4.33% | 0.00% | |
| 8 | Wolverine Asset ManagementWolverine | $18.7M | 4.08% | +3.34% | |
| 9 | Polar Asset Management PartnersPolar Asset Management Partners | $15.1M | 3.30% | 0.00% | |
| 10 | TENOR CAPITAL MANAGEMENTTENOR | $15.1M | 3.30% | 0.00% | |
| 11 | D. E. ShawD. E. Shaw | $14.8M | 3.24% | +6.11% | |
| 12 | CNH PartnersCNH Partners | $11.4M | 2.49% | +1.70% | |
| 13 | Aristeia CapitalAristeia Capital | $11.1M | 2.42% | 0.00% | |
| 14 | Crossingbridge AdvisorsCrossingbridge | $11.1M | 2.42% | +214.29% | |
| 15 | Vivaldi Asset ManagementVivaldi | $10.7M | 2.35% | 0.00% | |
| 16 | Omers AdministrationOmers Administration | $10.1M | 2.20% | 0.00% | |
| 17 | Davidson Kempner Capital ManagementDavidson Kempner | $10.1M | 2.20% | 0.00% | |
| 18 | Picton Mahoney Asset ManagementPicton Mahoney | $8.9M | 1.95% | +1.49% | |
| 19 | Two Sigma InvestmentsTwo Sigma | $8.9M | 1.95% | 0.00% | |
| 20 | Context Capital ManagementContext | $7.5M | 1.65% | 0.00% | |
| 21 | Moore Capital ManagementMoore | $7.5M | 1.65% | 0.00% | |
| 22 | Ghisallo Capital ManagementGhisallo | $7.5M | 1.65% | 0.00% | |
| 23 | Mercuria Capital StrategiesMercuria Capital Strategies | $7.5M | 1.65% | 0.00% | |
| 24 | Westchester Capital ManagementWestchester | $6.3M | 1.37% | +24.36% | |
| 25 | Radcliffe Capital ManagementRadcliffe | $5.8M | 1.27% | 0.00% |
70 managers report $457.6M of Drugs Made In America Acquisition II on form 13F for the quarter ended Jun 30 '26. 27 of them hold 80% of it; Karpus is largest at 6.13%.
Drugs Made In America Acquisition II Corp.
10.20
Expected move
No implied move.